Skip to main content
Log in

The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas

  • Article
  • Published:
Pathology & Oncology Research

Abstract

The current WHO classification of human astrocytomas has limitations in predicting prognosis and diagnosis, and there is a need for additional factors. Several studies have investigated the clinical value of proliferative activity in these tumors, especially the Ki-67/MIB-1 labeling index (LI). The aim of this study was to review the literature on this topic to get a survey of the current experience. All studies show increasing values of Ki-67/MIB-1 LI with increasing grade of malignancy. Most of them demonstrate that MIB-1 LI differentiates well between diffuse astrocytomas WHO grade II (AII) and anaplastic astrocytomas (AA) and between AII and glioblastomas (GM), but not between AA and GM. There is, however, considerable overlap of indices between the different malignancy groups. Further, in most studies positive correlations between MIB-1 LI and survival are found, though the proposed cut-off values vary substantially between the reports. The studies reviewed report MIB-1 LI as an important prognostic factor in human astrocytomas. Due to the great spread of values between the various tumor grades, however, MIB-1 LI cannot be used as a diagnostic factor alone but should be used in combination with established criteria of histological malignancy. It may be especially useful in cases where histology reveals a low-grade astrocytoma whereas other parameters indicate a more malignant neoplasm. Thus, it is our opinion that MIB-1 LI should be a part of the routine investigation in patients with astrocytic tumors. Until larger multicenter studies based on standardized immunohistopathological procedures have been completed, each laboratory has to establish its own practice. (Pathology Oncology Research Vol 12, No 3, 143–147)

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Di Nishizaki T, Harada K, et al: Proliferative potentials of glioma cells and vascular components determined with monoclonal antibody MIB-1. J Exp Clin Canc Res 16:389–394, 1997

    Google Scholar 

  2. Eneström S, Vavruch L, Frånlund B, et al: Ki-67 antigen expression as a prognostic factor in primary and recurrent astrocytomas. Neurochir 44:25–30, 1998

    Google Scholar 

  3. Gerdes J, Schwab U, Lemke H, et al: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31:13–20, 1983

    Article  PubMed  CAS  Google Scholar 

  4. Gerdes J, Li L, Schlueter, et al: Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 138: 867–873, 1991

    PubMed  CAS  Google Scholar 

  5. Hilton DA, Love S, Barber R, et al: Accumulation of p53 and Ki-67 expression do not predict survival in patients with fibrillary astrocytomas or the response of these tumors to radiotherapy. Neurosurgery 42:724–729, 1998

    Article  PubMed  CAS  Google Scholar 

  6. Hsu DW, Louis DN, Efird JT, et al: Use of MIB-1 (Ki-67) immunoreactivity in differentiating grade II and grade III gliomas. J Neuropathol Exp Neurol 56:857–865, 1997

    Article  PubMed  CAS  Google Scholar 

  7. Karamitopoulou E, Perentes E, Diamantis I, et al: Ki-67 immunoreactivity in human central nervous system tumors: a study with MIB 1 monoclonal antibody on archival material. Acta Neuropathol 87:47–54, 1994

    PubMed  CAS  Google Scholar 

  8. Key G, Becker MHG, Baron B, et al: New Ki-67-equivalent murine monoclonal antibodies (MIB 1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope. Lab Invest 68: 629–636, 1993

    PubMed  CAS  Google Scholar 

  9. Khalid H, Shibata S, Kishikawa M, et al: Immunohistochemical analysis of progesterone receptor and Ki-67 labeling index in astrocytic tumors. Cancer 80: 2133–2140, 1997

    Article  PubMed  CAS  Google Scholar 

  10. Kleihuses P, Cavanee WK: World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Nervous System. IARC Press, Lyon, 2000

    Google Scholar 

  11. McKeever PE, Ross DA, Strawderman MS, et al: A comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters. J Neuropathol Exp Neurol 56:798–805, 1997

    PubMed  CAS  Google Scholar 

  12. McKeever PE, Strawderman MS, Yamini B, et al: MIB-1 proliferation index predicts survival among patients with grade II astrocytoma. J Neuropathol Exp Neurol 57:931–936, 1998

    Article  PubMed  CAS  Google Scholar 

  13. Neder L, Colli BO, Machado HR, et al: MIB-1 labeling index in astrocytic tumors—a clinicopathologic study. Clin Neuropathol 6: 262–270, 2004

    Google Scholar 

  14. Ralte AM, Sharma MC, Karak AK, et al: Clinicopathological features, MIB-1 labeling index and apoptotic index in recurrent astrocytic tumors. Pathol Oncol Res 7:267–278, 2001

    Article  PubMed  CAS  Google Scholar 

  15. Reavey-Cantwell JF, Haroun RI, Zahurak M, et al: The prognostic value of tumor markers in patients with glioblastoma multiforme: analysis of 32 patients and review of the literature. J Neuro-Oncol 55:195–204, 2001

    Article  CAS  Google Scholar 

  16. Sallinen PK, Haapasalo HK, Visakorpi T, et al: Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded samples. J Pathol 174: 275–282, 1994

    Article  PubMed  CAS  Google Scholar 

  17. Schiffer D, Cavalla P, Chiò A, et al: Proliferative activity and prognosis of low-grade astrocytomas. J Neuro-Oncol 34:31–35, 1997

    Article  CAS  Google Scholar 

  18. Torp SH: Diagnostic and prognostic role of Ki67 immunostaining in human astrocytomas using four different antibodies. Clin Neouropathol 21:252–257, 2002

    CAS  Google Scholar 

  19. Torp SH, Alsaker M: Ki-67 immunoreactivity, basic fibroblast growth factor (bFGF) expression, and microvessel density as supplementary prognostic tools in low-grade astrocytomas. Pathol Res Pract 198:261–265, 2002

    PubMed  CAS  Google Scholar 

  20. Wakimoto H, Aoyagi M, Nakayama T, et al: Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas. Cancer 77:373–380, 1996

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sverre Helge Torp MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Johannessen, A.L., Torp, S.H. The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas. Pathol. Oncol. Res. 12, 143–147 (2006). https://doi.org/10.1007/BF02893360

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02893360

Key words

Navigation